Israel - English - Ministry of Health

merck sharp & dohme (israel - 1996) company ltd, israel - pneumococcal vaccine polyvalent - solution for injection - pneumococcal vaccine polyvalent 25 mcg / 0.5 ml - pneumococcus, purified polysaccharides antigen - pneumococcus, purified polysaccharides antigen - for vaccination against pneumococcal disease caused by those pneumococcal types included in the vaccine.

New Zealand - English - Medsafe (Medicines Safety Authority)

merck sharp & dohme (new zealand) limited - pneumococcal polysaccharide vaccine 50 µg/ml (25mcg/dose of each of 23 named pneumococcal polysaccharides) - solution for injection - active: pneumococcal polysaccharide vaccine 50 µg/ml (25mcg/dose of each of 23 named pneumococcal polysaccharides) excipient: phenol sodium chloride water for injection - pneumovax 23 is indicated for vaccination against pneumococcal disease caused by those pneumococcal types included in the vaccine.

Australia - English - Department of Health (Therapeutic Goods Administration)

merck sharp & dohme (australia) pty ltd - pneumococcal purified capsular polysaccharides, quantity: 50 microgram/ml - injection, solution - excipient ingredients: water for injections; phenol; sodium chloride - pneumovax 23 is indicated for immunisation of individuals in the following situations: all individuals over the age of 65 years; individuals with asplenia, either functional or anatomical, including sickle cell disease, in persons more than 2 years of age; where possible the vaccine should be given at least 14 days before splenectomy; immunocompromised patients at increased risk of pneumococcal disease (eg patients with hiv infection before the development of aids, nephrotic syndrome, multiple myeloma, lymphoma, hodgkin's disease and organ transplantation); aboriginal and torres strait islander people over 50 years of age; immunocompetent persons at increased risk of complications from pneumococcal disease because of chronic illness (eg chronic cardiac, renal or pulmonary disease, diabetes mellitus, alcoholism and cirrhosis); patients with cerebrospinal fluid leaks. in australia, the national health and medical research council (nhmrc) currently recommends the vaccination of tobacco smokers with the 23-valent

Australia - English - Department of Health (Therapeutic Goods Administration)

merck sharp & dohme (australia) pty ltd - pneumococcal purified capsular polysaccharides, quantity: 50 microgram/ml - injection, solution - excipient ingredients: water for injections; phenol; sodium chloride - pneumovax 23 is indicated for immunisation of individuals in the following situations: all individuals over the age of 65 years; individuals with asplenia, either functional or anatomical, including sickle cell disease, in persons more than 2 years of age; where possible the vaccine should be given at least 14 days before splenectomy; immunocompromised patients at increased risk of pneumococcal disease (eg patients with hiv infection before the development of aids, nephrotic syndrome, multiple myeloma, lymphoma, hodgkin's disease and organ transplantation); aboriginal and torres strait islander people over 50 years of age; immunocompetent persons at increased risk of complications from pneumococcal disease because of chronic illness (eg chronic cardiac, renal or pulmonary disease, diabetes mellitus, alcoholism and cirrhosis); patients with cerebrospinal fluid leaks. in australia, the national health and medical research council (nhmrc) currently recommends the vaccination of tobacco smokers with the 23-valent polysaccharide pneumococcal vaccine. pneumovax 23 is indicated for immunisation only against pneumococcal disease caused by those pneumococcal types included in the vaccine. effectiveness of the vaccine in the prevention of pneumococcal pneumonia and pneumococcal bacteremia has been demonstrated. in australia, the national health and medical research council (nhmrc) currently recommeds the vaccination of tabacco smokers with the 23-valent polysaccharide pneumococcal vaccine. pneumovax 23 will not prevent disease caused by capsular types of pneumococcus othar those contained in the vaccine.

Ireland - English - HPRA (Health Products Regulatory Authority)

sanofi pasteur msd ltd - pneumococcal vaccine - solution for injection - 25mcg/0.5m %v/v - pneumococcal vaccines

Ireland - English - HPRA (Health Products Regulatory Authority)

merck sharp & dohme ireland (human health) limited - pneumococcal vaccine - solution for injection in pre-filled syringe - 25 mcg/0.5 millilitre(s) - pneumococcal vaccines; pneumococcus, purified polysaccharides antigen

Ireland - English - HPRA (Health Products Regulatory Authority)

merck sharp & dohme ireland (human health) limited - pneumococcal vaccine - solution for injection - 25mcg/0.5 millilitre(s) - pneumococcal vaccines; pneumococcus, purified polysaccharides antigen

Ireland - English - HPRA (Health Products Regulatory Authority)

sanofi pasteur msd ltd - pneumococcal polysaccharide serotype 1, pneumococcal polysaccharide type 2 (2), pneumococcal polysaccharide type 3 (3), pneumococcal polysaccharide serotype 4, pneumococcal polysaccharide serotype 5, pneumococcal polysaccharide serotype 6b, pneumococcal polysaccharide serotype 7f, pneumococcal polysaccharide type 8 (8), pneumococcal polysaccharide type 9n, pneumococcal polysaccharide serotype 9v, pneumococcal polysaccharide type 20 (20), pneumococcal oligosaccharide serotype 18c, pneumococcal polysaccharide - solution for injection in pre-filled syringe - 25/0.5 microgram/ml - pneumococcal vaccines - it is recommended for active immunisation against disease caused by the pneumococcal serotypes included in the vaccine

Australia - English - Department of Health (Therapeutic Goods Administration)

merck sharp & dohme (australia) pty ltd - live varicella vaccine, quantity: 19400 pfu - injection, powder for - excipient ingredients: dibasic sodium phosphate; sodium chloride; urea; potassium chloride; sucrose; monobasic potassium phosphate; monosodium glutamate monohydrate; hydrolysed gelatin - zostavax is indicated for the prevention of herpes zoster (shingles) in individuals 50 years of age and older. zostavax is indicated for the prevention of postherpetic neuralgia (phn) and for reduction of acute and chronic zoster-associated pain in individuals 60 years of age and older.

Australia - English - Department of Health (Therapeutic Goods Administration)

merck sharp & dohme (australia) pty ltd - live varicella vaccine, quantity: 19400 pfu - injection, powder for - excipient ingredients: monosodium glutamate monohydrate; sodium chloride; sucrose; hydrolysed gelatin; dibasic sodium phosphate; monobasic potassium phosphate; potassium chloride; urea - zostavax is indicated for the prevention of herpes zoster (shingles) in individuals 50 years of age and older. zostavax is indicated for the prevention of postherpetic neuralgia (phn) and for reduction of acute and chronic zoster-associated pain in individuals 60 years of age and older.